Spiera, Robert

Trial of tocilizumab in giant-cell arteritis

Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine

Vasculitis and related conditionsRheumatoid Arthritis Research and Therapies

Cited by 1,386

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation

Systemic Sclerosis and Related DiseasesConnective tissue disorders research

Cited by 351

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

Spiera, R., Jinich, S., & Jannat-Khah, D. (2021) · Annals of the Rheumatic Diseases

SARS-CoV-2 and COVID-19 ResearchRheumatoid Arthritis Research and Therapies

Cited by 180

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Spiera, R. F., Gordon, J. K., Mersten, J. N., Magro, C. M., Mehta, M., Wildman, H. F., Kloiber, S., Kirou, K. A., Lyman, S., & Crow, M. K. (2011) · Annals of the Rheumatic Diseases

Systemic Sclerosis and Related DiseasesConnective tissue disorders research

Cited by 173